National Patient Safety Alert
Shortage of GLP-1 receptor agonists update.
Published: 3 January 2024
The supply of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to be limited, with supply not expected to return to normal until at least the end of 2024.
The supply issues have been caused by an increase in demand for these products for licensed and off-label indications. GLP-1 RAs licensed for T2DM should not be prescribed for off-label indications. Existing stock must be conserved for patients with T2DM to mitigate the risk of impaired access to treatment and increased risk in diabetes related complications.
This National Patient Safety Alert provides further background and clinical information and actions required.